Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.

First data with the biotech’s new EGFR project prompts a 236% share price bump.

The company puts its faith in a new lymphodepletion regimen to overcome mediocre early results with its lead Car-NK therapy.

Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.

Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.

Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.